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Council,10 despite evidence that patients thought the
Nuffield recommendations were appropriate.11 The
Department of Health for England has so far taken a
similar line to theMRC.1 Implied consent is accepted by
the Department of Health for using “surplus” tissues in
quality control,12 but explicit consent is now the norm
for research.1 The latest proposals now demand explicit
consent for teaching, which will pose problems—
especially in histopathology.13 Using tissue without
consent will be a criminal offence.
Acting on individual patients’ wishes has implica-
tions for resources. An efficient system to record and
retrieve those wishes is required, whether explicit or
implied consent is used. This is already needed even to
check for objectives to use of human tissue samples in
teaching and quality control. Yet at a recent meeting of
academic pathologists in Bristol, not one participant
could claim that his or her local hospital had
implemented such a system. So research is being
inhibited; but for teaching, quality control, and audit,
consent issues are still being ignored.
If we are serious about empowering patients to
control the use of their tissue samples, resources must
be allocated irrespective of whether implied or explicit
consent is regarded as appropriate. Without such
resources our laboratories are forced into paralysis or
continuing paternalism. At present we have both.
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Blindness in children
Half of it is avoidable, and suitable cost effective interventions are available
Childhood blindness is a priority of “Vision2020—the Right to Sight,” a global initiative forthe elimination of avoidable blindness
(www.v2020.org), although only 1.4m blind children are
included in the worldwide total of 45m blind people .1 2
There are several reasons for this. Blind children have a
lifetime of blindness ahead, which affects their opportu-
nities for education, employment, and earning potential.
Early onset blindness adversely affects psychomotor,
social, and emotional development. Blind children have
a higher death rate than their sighted counterparts. An
estimated 500 000 children become blind each year, but
in developing countries up to 60% are thought to die
within a year of becoming blind.2 Almost half of all
blindness in children—particularly those in the poorest
communities3—is due to avoidable causes that are
amenable to cost effective interventions.
The prevalence of blindness is higher in develop-
ing countries because, firstly, potentially blinding
conditions such as vitamin A deficiency, harmful
traditional eye remedies, or cerebral malaria, which do
not occur in affluent societies, are prevalent there. Sec-
ondly, preventive measures for conditions that have
been controlled elsewhere such as measles, congenital
rubella, or ophthalmia neonatorum are inadequate.
Thirdly, facilities and skilled personnel for managing
conditions needing surgery are lacking (box).4
In middle income countries the pattern of causes is
mixed, with retinopathy of prematurity emerging as an
important cause in Latin America and some eastern
European countries.5 6 Currently unavoidable causes
(the biggest group in affluent countries) include
hereditary retinal dystrophies, disorders of the central
nervous system, and congenital anomalies. Uncor-
rected refractive errors cause visual impairment and
Box 1 Magnitude and causes of blindness in
children
• The epidemiology of blindness in children reflects
socioeconomic development
• The prevalence and magnitude ranges from about
3/10 000 children in affluent societies (60 blind
children per million total population) to 15/10 000 in
the poorest communities (600 blind children per
million total population)
• 75% of the world’s blind children live in developing
countries
• Some 500 000 children become blind each year,
most in developing countries
• Blind children have a high death rate—the
prevalence therefore markedly underestimates the
burden2
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blindness in all regions, particularly myopia in south
east Asia.7
Children younger than 5 years need targeting as
this age group has the highest incidence of blindness,
and early sight restoring surgery is needed to prevent
amblyopia. Priorities include elimination of corneal
scarring due to vitamin A deficiency, and measles
(poorest communities); treatment of cataract (every-
where), screening programmes for retinopathy of pre-
maturity (middle income countries), correction with
spectacles for refractive errors (everywhere); and low
vision services for children with incurable visual loss
(everywhere).
About 140m children have vitamin A deficiency
disorders and are at risk of blindness and increased
mortality.8 Massive international and national efforts
for control are in place in countries with death rates
among children younger than 5 of more than 50 per
1000 live births, where vitamin A deficiency disorders
are prevalent. Control encompasses promotion of
breast feeding, home gardening (to increase local pro-
duction of food rich in vitamin A, control of diarrhoea,
fortification of food, education about nutrition, and
intermittent supplementation with high dose vitamin
A. Since the launch of the vitamin A global initiative in
1998 supplements are combined with immunisation.
Between 1998 and 2000 about a million child deaths
were prevented.9 However, the impact on blindness is
more difficult to ascertain, but blind school and
community studies show that corneal blindness is less
common in young than in older children.10
Measles causes corneal blindness through several
mechanisms, including acute vitamin A deficiency,
exposure keratitis, herpes simplex keratitis, secondary
infection, and harmful traditional remedies. As a result
of the Expanded Programme of Immunisation, the
number of cases with measles has fallen from over 4m
per year in 1980 to 830 000 in 2001, and global immu-
nisation coverage is currently 72%.11 Declining rates of
measles related blindness in parallel with increasing
immunisation coverage has been reported, and
according to anecdotal evidence corneal ulceration
after measles is now uncommon in developing
countries.
The management of childhood cataract is far
more complex than age related cataract and needs
well trained teams at the tertiary level and long term
follow up. Children with cataract need to be identified
and referred promptly, and barriers overcome
through health education—for example, fear that eyes
are removed during surgery. In many developing
countries, particularly in Africa, paediatric ophthal-
mology is underdeveloped, but training programmes
are becoming established, particularly in India, to
meet targets set by Vision 2020 of at least one trained
paediatric ophthalmologist for every 50m population
by 2010.2 Vision 2020 aims to reduce the global
prevalence of blindness in children from the current
level of 7/10 000 children to 4/10 000 by 2020. If
achieved, the number of blind children would be
almost halved, as the child population is projected to
stabilise at 2bn over the next few years.
Excellent neonatal care can prevent retinopathy of
prematurity to a large extent, but babies developing
threshold disease need to be identified as treatment of
this stage is highly effective at preventing visual loss.12
Screening programmes are in place in industrialised
countries and are being developed in Latin America
and large Asian cities.
Many children with incurable visual loss benefit from
low vision services, which facilitate near vision and inclu-
sive education. Often these services are lacking where
they are most needed. Refractive errors, particularly
myopia, often go undetected, and vision screening in
schools with provision of affordable spectacles is
another component of Vision 2020.
The control of blindness in children is complex,
requiring community activities through to sophisticated
tertiary eye care services (figure). Multidisciplinary
collaboration will be required with comprehensive
service delivery encompassing health promotion,
specific preventive measures, optical, medical, and surgi-
cal services as well as low vision care, special education,
and rehabilitation. The challenges are to ensure political
commitment towards the alleviation of poverty and the
development of models that are effective, replicable,
sustainable, and equitable and to mobilise the additional
resources required.
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